AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17976264 — intervention group
Group type: COMPARATOR
Intervention: Solid meal (shepherd's pie)
Number of subjects: 0
Study 16088266 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment and repeated thermal therapy (far-infrared ray dry sauna therapy and post-sauna warming, once a day for 4 weeks)
Number of subjects: 46
Study 16088266 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary treatment (cognitive behavioral therapy, rehabilitation, and exercise therapy)
Number of subjects: 46
Study 12805913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (600 mg + 5 mg/ml adrenaline)
Number of subjects: 30
Study 12805913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (600 mg + 5 microg/ml adrenaline)
Number of subjects: 30
Study 9505892 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose enteric coated pancreatin enzyme supplementation
Number of subjects: 21
Study 9505892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7893297 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT (4% lidocaine, 1:2,000 adrenaline, 1% tetracaine)
Number of subjects: 95
Study 7893297 — intervention group
Group type: COMPARATOR
Intervention: TAC (0.5% tetracaine, 1:2,000 adrenaline, 11.8% cocaine)
Number of subjects: 95
Study 2128929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional preparation (CP)
Number of subjects: 1265
Study 2128929 — intervention group
Group type: COMPARATOR
Intervention: Total digestive irrigation (TDI)
Number of subjects: 1265
Study 2128929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional preparation (CP) with Sennosides
Number of subjects: 1265
Study 2128929 — intervention group
Group type: COMPARATOR
Intervention: 2 liters of 10% Mannitol
Number of subjects: 1265
Study 2128929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lukewarm water enemas
Number of subjects: 1265
Study 2128929 — intervention group
Group type: COMPARATOR
Intervention: Enemas with iodinated polyvidone diluted to 5%
Number of subjects: 1265
Study 2128929 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy utilizing Metronidazole
Number of subjects: 1265
Study 2128929 — intervention group
Group type: COMPARATOR
Intervention: 24-hour antibiotic therapy utilizing Metronidazole (1.5 g) and/or Cefotaxime (4 g)
Number of subjects: 1265
Study 75643 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus isolation
Number of subjects: 32
Study 75643 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescent staining (IF‐test)
Number of subjects: 32
Study 75643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tzanck smears
Number of subjects: 32
Study 75643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of any two diagnostic methods
Number of subjects: 32
Study 75643 — intervention group
Group type: COMPARATOR
Intervention: IF‐test and Tzanck smear
Number of subjects: 32
Study 30404085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy-enhanced SSE
Number of subjects: 0
Study 30404085 — intervention group
Group type: COMPARATOR
Intervention: Naked-eye SSE
Number of subjects: 0
Study 25267326 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention (EQUIP)
Number of subjects: 1200
Study 25267326 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained endoscopists)
Number of subjects: 1200
Study 25800417 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative behavioral couple therapy
Number of subjects: 134
Study 25800417 — intervention group
Group type: COMPARATOR
Intervention: Traditional behavioral couple therapy
Number of subjects: 134
Study 21859315 — intervention group
Group type: COMPARATOR
Intervention: EPB (Control)
Number of subjects: 100
Study 21859315 — intervention group
Group type: COMPARATOR
Intervention: DPB (Control)
Number of subjects: 100
Study 21859315 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHF(9.5)
Number of subjects: 100
Study 21859315 — intervention group
Group type: EXPERIMENTAL
Intervention: EPHF(5)
Number of subjects: 100
Study 21859315 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF(9.5)P
Number of subjects: 100
Study 21859315 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF(5)P
Number of subjects: 100
Study 21859315 — intervention group
Group type: EXPERIMENTAL
Intervention: DPHF(9.5)
Number of subjects: 100
Study 21859315 — intervention group
Group type: EXPERIMENTAL
Intervention: DHF(5)P
Number of subjects: 100
Study 19884554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 170
Study 19884554 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and Carboplatin
Number of subjects: 170
Study 19884554 — intervention group
Group type: EXPERIMENTAL
Intervention: RRM1 protein levels
Number of subjects: 170
Study 19884554 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC1 protein levels
Number of subjects: 170
Study 19884554 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for response prediction including RRM1, ERCC1, and treatment arm
Number of subjects: 170
Study 19884554 — intervention group
Group type: EXPERIMENTAL
Intervention: RRM1 and ERCC1 levels
Number of subjects: 170
Study 17084905 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused psychoeducation and pharmacotherapy
Number of subjects: 38
Study 15316128 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 1255
Study 15316128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 11348951 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 283
Study 11348951 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 283
Study 9205823 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 7
Study 9205823 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 7
Study 8240465 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen/placebo (stomach) 0.9 ± 0.1
Number of subjects: 20
Study 8240465 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen/placebo (duodenum) 0.0 ± 0.0
Number of subjects: 20
Study 8240465 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen/ranitidine (stomach) 0.8 ± 0.1
Number of subjects: 20
Study 8240465 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen/ranitidine (duodenum) 0.1 ± 0.1
Number of subjects: 20
Study 8240465 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen/placebo (duodenum) 0.2 ± 0.1
Number of subjects: 20
Study 8240465 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen/ranitidine (stomach) 0.9 ± 0.1
Number of subjects: 20
Study 2822066 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium-induced intense neuromuscular blockade with halothane
Number of subjects: 60
Study 2822066 — intervention group
Group type: COMPARATOR
Intervention: Atracurium-induced intense neuromuscular blockade with fentanyl
Number of subjects: 60
Study 2822066 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-tetanic count (PTC) method
Number of subjects: 60
Study 2822066 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) response
Number of subjects: 60
Study 31548130 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Kscore test followed by mpMRI
Number of subjects: 266
Study 31548130 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial mpMRI followed by biopsy for negative mpMRI (PI-RADS 1-2) if the 4Kscore was >18% or PSAd was >0.10ng/ml/cm3
Number of subjects: 266
Study 31548130 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Kscore test
Number of subjects: 266
Study 31548130 — intervention group
Group type: EXPERIMENTAL
Intervention: PSAd <0.10ng/ml/cm3
Number of subjects: 266
Study 31548130 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC-RC <2%
Number of subjects: 266
Study 29929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet treatment
Number of subjects: 119
Study 29929375 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Ectasia (CAE)
Number of subjects: 119
Study 29929375 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Ectasia (CAE) + AMI
Number of subjects: 119
Study 29929375 — intervention group
Group type: COMPARATOR
Intervention: Coronary Heart Disease (control)
Number of subjects: 119
Study 29929375 — intervention group
Group type: COMPARATOR
Intervention: Normal Coronary Arteries (control)
Number of subjects: 119
Study 29929375 — intervention group
Group type: COMPARATOR
Intervention: AMI patients without CAE (AMI group)
Number of subjects: 119
Study 28226183 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management workshop for young people and parents
Number of subjects: 22
Study 25801699 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 566
Study 23631832 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation using iPlan software
Number of subjects: 20
Study 23631832 — intervention group
Group type: COMPARATOR
Intervention: Human observers
Number of subjects: 20
Study 21334025 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction followed by standard running vesicourethral anastomosis
Number of subjects: 94
Study 21334025 — intervention group
Group type: COMPARATOR
Intervention: Standard running vesicourethral anastomosis (control)
Number of subjects: 94
Study 21334025 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction
Number of subjects: 94
Study 19050050 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zoledronate
Number of subjects: 50
Study 19050050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17007757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid group (prednisolone 2mg/kg/day on alternate days, tapered over 8 weeks)
Number of subjects: 75
Study 17007757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-lesional steroid group (triamcinolone 1 to 5 mg/kg, max 30mg, six injections monthly)
Number of subjects: 75
Study 17007757 — intervention group
Group type: COMPARATOR
Intervention: Control group (managed conservatively with repeated hospital visits)
Number of subjects: 75
Study 17007757 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid group
Number of subjects: 75
Study 17007757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-lesional steroid group
Number of subjects: 75
Study 15362027 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (50 mg daily)
Number of subjects: 131
Study 15362027 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalamine (3 g daily)
Number of subjects: 131
Study 15362027 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 131
Study 11493295 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel dressings
Number of subjects: 0
Study 11493295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsilicone gel dressings
Number of subjects: 0
Study 11493295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9923728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 6
Study 9923728 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 6
Study 9923728 — intervention group
Group type: EXPERIMENTAL
Intervention: Post treadmill exercise skill test
Number of subjects: 6
Study 9923728 — intervention group
Group type: EXPERIMENTAL
Intervention: Order by time effect for hematocrit
Number of subjects: 6
Study 9923728 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose, plasma lactate, hemoglobin concentrations
Number of subjects: 6
Study 9923728 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass
Number of subjects: 6
Study 8063434 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothpaste containing the lactoperoxidase system
Number of subjects: 12
Study 8063434 — intervention group
Group type: COMPARATOR
Intervention: Normal fluoridated toothpaste
Number of subjects: 12
Study 3057815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg/day)
Number of subjects: 27
Study 3057815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31771385 — intervention group
Group type: COMPARATOR
Intervention: C+P (conventional carious lesion management with prevention)
Number of subjects: 1144
Study 31771385 — intervention group
Group type: EXPERIMENTAL
Intervention: B+P (biological management with prevention)
Number of subjects: 1144
Study 31771385 — intervention group
Group type: EXPERIMENTAL
Intervention: PA (prevention alone)
Number of subjects: 1144
Study 29653527 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer intervention based on the Theory of Planned Behavior (TPB)
Number of subjects: 0
Study 29653527 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29045105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 60
Study 29045105 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 60
Study 25602891 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard support communities receiving modest funding to implement Stepping On
Number of subjects: 150
Study 25602891 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support communities receiving funding and technical support
Number of subjects: 150
Study 25602891 — intervention group
Group type: COMPARATOR
Intervention: Control communities receiving no special resources or guidance on fall prevention
Number of subjects: 150
Study 23880195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy for 2 years
Number of subjects: 187
Study 23880195 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 187
Study 23880195 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of treatment groups
Number of subjects: 187
Study 21071361 — intervention group
Group type: EXPERIMENTAL
Intervention: O+O (oral stimulation)
Number of subjects: 75
Study 21071361 — intervention group
Group type: EXPERIMENTAL
Intervention: T/K+T/K (tactile/kinesthetic stimulation)
Number of subjects: 75
Study 21071361 — intervention group
Group type: EXPERIMENTAL
Intervention: O+T/K (combined intervention)
Number of subjects: 75
Study 21071361 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 18186973 — intervention group
Group type: COMPARATOR
Intervention: CQ alone
Number of subjects: 15
Study 18186973 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-CP
Number of subjects: 15
Study 18186973 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-PR
Number of subjects: 15
Study 17010806 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy with elastic bandage of the legs (compression pressure 40 to 60 mm Hg) and abdomen (compression pressure 20 to 30 mm Hg) for 10 min each.
Number of subjects: 21
Study 17010806 — intervention group
Group type: COMPARATOR
Intervention: Sham leg bandage and sham abdominal bandage.
Number of subjects: 21
Study 17010806 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy with elastic compression stockings of the legs (prescribed in all patients).
Number of subjects: 21
Study 12717396 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study 12717396 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 72
Study 9826312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (1.0 g BID)
Number of subjects: 36
Study 9826312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7522004 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser
Number of subjects: 0
Study 7522004 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton red laser
Number of subjects: 0
Study 7522004 — intervention group
Group type: COMPARATOR
Intervention: Both laser treatments
Number of subjects: 0
Study 2681673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 96
Study 2681673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 96
Study 2681673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1084825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 240 mg
Number of subjects: 40
Study 1084825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg
Number of subjects: 40
Study 1084825 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 4.8 gm
Number of subjects: 40
Study 1084825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31222344 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary intake of molybdenum (Mo) and cadmium (Cd)
Number of subjects: 60
Study 31222344 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Mo and Cd co-treated group
Number of subjects: 60
Study 31222344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination groups (Mo and Cd co-exposure)
Number of subjects: 60
Study 31222344 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-exposure groups (Mo and Cd)
Number of subjects: 60
Study 29072167 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 8
Study 23425313 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated renal care network
Number of subjects: 160
Study 23425313 — intervention group
Group type: COMPARATOR
Intervention: Standard renal care in nephrology departments
Number of subjects: 160
Study 21555773 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg of teriparatide once daily for 28 days
Number of subjects: 24
Study 21555773 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 24
Study 19555809 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (1.5 g bid)
Number of subjects: 33
Study 19555809 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg qd) with L-arginine
Number of subjects: 33
Study 19555809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17200474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab (2 mg/kg intravenous bolus prior to PCI followed by 0.05 mg/kg per hour infusion over 24 hours)
Number of subjects: 5745
Study 17200474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5745
Study 17200474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 5745
Study 15070948 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 13
Study 15070948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11453960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (5 or 10 mg)
Number of subjects: 32
Study 11453960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11453960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg)
Number of subjects: 32
Study 11453960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone responders
Number of subjects: 32
Study 11453960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone nonresponders
Number of subjects: 32
Study 9622184 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention biased towards left location
Number of subjects: 0
Study 9622184 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention biased towards right location
Number of subjects: 0
Study 9622184 — intervention group
Group type: COMPARATOR
Intervention: Divided attention condition
Number of subjects: 0
Study 9622184 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention biased towards left or right location
Number of subjects: 0
Study 7912766 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome influenza vaccine
Number of subjects: 126
Study 7912766 — intervention group
Group type: COMPARATOR
Intervention: Commercial whole-virus vaccine
Number of subjects: 126
Study 7912766 — intervention group
Group type: COMPARATOR
Intervention: Subunit vaccine
Number of subjects: 126
Study 2073959 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill enzyme treatment
Number of subjects: 31
Study 2073959 — intervention group
Group type: COMPARATOR
Intervention: Non-enzymatic treatment
Number of subjects: 31
Study 781227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen (400 mg Q6H)
Number of subjects: 116
Study 781227 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1,000 mg Q6H)
Number of subjects: 116
Study 781227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 31562758 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance olaparib (300 mg b.i.d.; tablets)
Number of subjects: 154
Study 28558366 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment in MDD patients with AIHM
Number of subjects: 2811
Study 28558366 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-AIHM
Number of subjects: 2811
Study 28558366 — intervention group
Group type: COMPARATOR
Intervention: MDD
Number of subjects: 2811
Study 28558366 — intervention group
Group type: COMPARATOR
Intervention: BD
Number of subjects: 2811
Study 26091286 — intervention group
Group type: EXPERIMENTAL
Intervention: BR-TD-1001 (test vaccine)
Number of subjects: 50
Study 26091286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26091286 — intervention group
Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 50
Study 23873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 75
Study 23873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + Valproate
Number of subjects: 75
Study 23873290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (coadministered with Valproate)
Number of subjects: 75
Study 23873290 — intervention group
Group type: COMPARATOR
Intervention: Lithium only
Number of subjects: 75
Study 21812168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient tracking/recall/outreach and provider prompts
Number of subjects: 6
Study 21812168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study 19449015 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy for slow-transit constipation
Number of subjects: 7
Study 16413699 — intervention group
Group type: EXPERIMENTAL
Intervention: Preradiotherapy treatment
Number of subjects: 210
Study 16413699 — intervention group
Group type: EXPERIMENTAL
Intervention: Postradiotherapy treatment
Number of subjects: 210